Waterdrop Inc. Announces Second Quarter 2025 Unaudited Financial Results and a Cash Dividend
Waterdrop Inc. (NYSE: WDH) reported strong Q2 2025 financial results, with net profit reaching RMB140.2 million (US$19.6 million), up 58.7% year-over-year. The company's insurance business showed exceptional growth with first-year premiums (FYP) of RMB3,204.3 million, increasing 80.2% year-over-year.
Key highlights include: net operating revenue of RMB838.0 million (up 23.9% YoY), significant AI integration improvements, and expansion of the E-Find Platform to 198 pharmaceutical partnerships. The Board approved an enhanced cash dividend of US$10.9 million (50% increase) and authorized a fifth annual share repurchase program of up to US$50 million.
The company completed the Shenlanbao acquisition and enhanced its medical crowdfunding platform with advanced AI capabilities, now covering 480 million donors and facilitating RMB70.0 billion in donations to 3.54 million patients.
Waterdrop Inc. (NYSE: WDH) ha annunciato solidi risultati finanziari per il 2° trimestre 2025: il utile netto è salito a RMB140,2 milioni (US$19,6 milioni), in aumento del 58,7% su base annua. Il segmento assicurativo ha registrato una crescita notevole con premi del primo anno (FYP) pari a RMB3.204,3 milioni, +80,2% YoY.
I punti chiave includono: ricavi operativi netti di RMB838,0 milioni (+23,9% YoY), significativi miglioramenti dovuti all'integrazione dell'IA e l'espansione della piattaforma E-Find a 198 partner farmaceutici. Il Consiglio ha approvato un dividendo in contanti potenziato di US$10,9 milioni (aumento del 50%) e ha autorizzato un quinto programma annuale di riacquisto azionario fino a US$50 milioni.
L'azienda ha completato l'acquisizione di Shenlanbao e potenziato la sua piattaforma di crowdfunding medico con avanzate funzionalità di IA, ora rivolta a 480 milioni di donatori e che ha consentito donazioni per RMB70,0 miliardi a 3,54 milioni di pazienti.
Waterdrop Inc. (NYSE: WDH) presentó sólidos resultados financieros del 2T 2025: el beneficio neto alcanzó RMB140,2 millones (US$19,6 millones), un aumento interanual del 58,7%. El negocio de seguros mostró un crecimiento destacado con primas del primer año (FYP) de RMB3.204,3 millones, +80,2% interanual.
Aspectos clave: ingresos operativos netos de RMB838,0 millones (subida del 23,9% interanual), mejoras significativas por la integración de IA y la ampliación de la plataforma E-Find a 198 socios farmacéuticos. La Junta aprobó un dividendo en efectivo mejorado de US$10,9 millones (incremento del 50%) y autorizó un quinto programa anual de recompra de acciones por hasta US$50 millones.
La compañÃa completó la adquisición de Shenlanbao y mejoró su plataforma de crowdfunding médico con capacidades avanzadas de IA, alcanzando ahora a 480 millones de donantes y facilitando donaciones por RMB70,0 mil millones a 3,54 millones de pacientes.
Waterdrop Inc. (NYSE: WDH)ëŠ� 2025ë…� 2분기 ê°•ë ¥í•� 실ì ì� 발표했습니다. 순ì´ìµì€ RMB140.2백만(미화 1,960ë§� 달러)으로 ì „ë…„ ë™ê¸° 대ë¹� 58.7% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ë³´í—˜ ë¶€ë¬¸ì€ íŠ¹ížˆ 호조ë¥� ë³´ì´ë©� 초회보험ë£�(FYP)ê°€ RMB3,204.3백만으로 ì „ë…„ 대ë¹� 80.2% ì¦ê°€í–ˆìŠµë‹ˆë‹¤.
주요 ë‚´ìš©: ì˜ì—…수ìµ(ìˆ�) RMB838.0백만(ì „ë…„ 대ë¹� 23.9% ì¦ê°€), AI 통합ì� 통한 성과 ê°œì„ , E-Find 플랫í¼ì˜ 198ê°� ì œì•½ 파트ë„� 확장. ì´ì‚¬íšŒëŠ” 현금배당 미화 1,090ë§� 달러(50% ì¦ì•¡)ë¥� 승ì¸í•˜ê³ , 최대 5,000ë§� 달러 규모ì� 다섯 번째 ì—°ë¡€ ìžì‚¬ì£� 매입 프로그램ì� 승ì¸í–ˆìŠµë‹ˆë‹¤.
회사ëŠ� Shenlanbao ì¸ìˆ˜ë¥� 완료했으ë©�, ê³ ê¸‰ AI 기능ì� 탑재í•� ì˜ë£Œ í¬ë¼ìš°ë“œíŽ€ë”� 플랫í¼ì„ ê°•í™”í•� 현재 4.8ì–� ëª…ì˜ ê¸°ë¶€ìž�ë¥� í¬ê´„í•˜ê³ ¸é²Ñµþ700¹®�ì� 354ë§� ëª…ì˜ í™˜ìžì—게 ì „ë‹¬í–ˆìŠµë‹ˆë‹¤.
Waterdrop Inc. (NYSE: WDH) a publié de solides résultats pour le 2e trimestre 2025 : le résultat net a atteint RMB140,2 millions (19,6 M$), en hausse de 58,7% en glissement annuel. Le segment assurance a connu une croissance remarquable avec des primes de première année (FYP) de RMB3 204,3 millions, +80,2% en glissement annuel.
Points clés : chiffre d'affaires d'exploitation net de RMB838,0 millions (en hausse de 23,9% en glissement annuel), améliorations significatives grâce à l'intégration de l'IA et extension de la plateforme E-Find à 198 partenaires pharmaceutiques. Le Conseil d'administration a approuvé un dividende en numéraire majoré de 10,9 M$ (augmentation de 50%) et a autorisé un cinquième programme annuel de rachat d'actions d'un montant pouvant aller jusqu'à 50 M$.
La société a finalisé l'acquisition de Shenlanbao et renforcé sa plateforme de financement participatif médical avec des capacités IA avancées, couvrant désormais 480 millions de donateurs et facilitant des dons de RMB70,0 milliards à 3,54 millions de patients.
Waterdrop Inc. (NYSE: WDH) meldete starke Finanzergebnisse für Q2 2025: der Nettogewinn stieg auf RMB140,2 Mio. (US$19,6 Mio.), ein Plus von 58,7% im Jahresvergleich. Das Versicherungsgeschäft wies besonderes Wachstum auf mit Erstjahresprämien (FYP) von RMB3.204,3 Mio., ein Anstieg von 80,2% YoY.
Wesentliche Punkte: Netto-Betriebserlöse von RMB838,0 Mio. (plus 23,9% YoY), substanzielle Verbesserungen durch KI-Integration und Ausbau der E-Find-Plattform auf 198 pharmazeutische Partner. Der Vorstand genehmigte eine erhöhte Bardividende von US$10,9 Mio. (50% Zuwachs) und autorisierte ein fünftes jährliches Aktienrückkaufprogramm von bis zu US$50 Mio..
Das Unternehmen schloss die Übernahme von Shenlanbao ab und verbesserte seine medizinische Crowdfunding-Plattform mit fortschrittlichen KI-Funktionen, die nun 480 Millionen Spender abdeckt und RMB70,0 Milliarden an Spenden für 3,54 Millionen Patienten vermittelt hat.
- Net profit increased by 58.7% year-over-year to RMB140.2 million (US$19.6 million)
- First-year premiums (FYP) grew 80.2% year-over-year to RMB3,204.3 million
- Operating profit increased 85.8% year-over-year to RMB97.3 million
- Board approved 50% increase in cash dividend to US$10.9 million
- New US$50 million share repurchase program authorized
- Insurance segment operating margin expanded by 2 percentage points
- Interest income decreased due to lower cash position
- Cash position declined to RMB3,406.7 million from RMB3,670.3 million in December 2024
- Crowdfunding segment reported operating loss of RMB32.1 million
- Medical crowdfunding service fees decreased 2.7% year-over-year
Insights
Waterdrop delivered robust Q2 2025 results with 58.7% profit growth, 80.2% premium growth, and a 50% dividend increase, driven by AI integration.
Waterdrop's Q2 2025 results show impressive growth across key metrics, with net profit reaching
Revenue diversification appears healthy, with insurance-related income climbing
Operating profit surged to
Waterdrop's strategic implementation of AI across its business operations appears to be paying dividends. The "Waterdrop Guardian" AI suite is delivering tangible results, with premiums facilitated by the 'AI Medical Insurance Expert' climbing
The company's capital allocation strategy reflects confidence in future prospects, with the Board approving a
The insurance segment stands out as the primary profit driver, generating an operating profit of
While the cash position decreased slightly to
Financial and Operational Highlights for the SecondÌý²Ï³Ü²¹°ù³Ù±ð°ù of 2025
- Further improvement in profitability: In the second quarter of 2025, net profit attributable to our ordinary shareholders reached
RMB140.2 million (US ), representing a solid increase of$19.6 million 58.7% year-over-year. We continued to generate positive operating cash flow during the second quarter of 2025. - Significant growth in insurance premiums: The first-year premiums ("FYP") generated through our insurance business reached
RMB3,204.3 million (US ) during the second quarter of 2025, representing an increase of$447.3 million 80.2% year-over-year. Net operating revenue wasRMB838.0 million (US ), representing an increase of$117.0 million 23.9% year-over-year. - MedicalÌýcrowdfunding coverage: As of June 30, 2025, around 480 million people had cumulatively donated an aggregate of
RMB70.0 billion to 3.54 million patients through Waterdrop Medical Crowdfunding. - Patient recruitment performance: As of June 30, 2025, the Company had cumulatively enrolled 12,216 patients into 1,385 clinical trial programs through theÌýE-Find Platform.
Mr.ÌýPeng Shen, Founder, Chairman, and Chief Executive Officer of Waterdrop, commented, "We are proud to announce that we have delivered strong revenue and profit, fueled by the further integration of AI into our sales and service processes.
The insurance business delivered an exceptional quarter. Year-over-year, FYP grew by
Our "Waterdrop Guardian" AI Application Suite constantly evolves, either interacting directly with end users or empowering our online consultants behind the scenes. Premiums facilitated by 'AI Medical Insurance Expert' climbed
On a separate note, we completed the acquisition of the remaining equity in Shenlanbao in June and anticipate further accelerating synergies.
During the second quarter, Waterdrop Medical Crowdfunding upgraded its risk assessment capabilities. A large-language-model ("LLM") engine now scans every campaign's content, comments and hidden clues, feeding insights into a smart matrix that tracks 15 high-risk scenarios, and refines itself to identify risks more accurately. Additionally, this quarter we partnered with
In this quarter, E-Find Platform expanded its collaboration to 198 pharmaceutical and contract research organizations. Meanwhile, we initiated services for 114 new programs. The number of patients enrolled also reached a historic high, with 999 patients enrolled in the second quarter of 2025, representing a
With a commitment to superior shareholder returns, we are pleased to announce that our board of directors of the Company (the "Board") has recently approved an enhanced cash dividend of
Looking ahead to the second half of 2025, we will strive to deliver both top-line and bottom-line growth. We believe that tech-driven innovation is the core strategy and source of business excellence, and look forward to delivering a compelling success story, as well as value to our users, partners and shareholders."Ìý
Financial Results for the Second Quarter of 2025
Operating revenue, net
Net operating revenue for the second quarter of 2025Ìýincreased byÌý
- Insurance-related income includes insurance brokerage income and technical service income. Insurance brokerage income represents brokerage commissions earned from insurance companies. Technical service income is derived from providing technical services including risk control technical service, user analytics and intelligent recommendation service, customer relationship maintenance, customer complaint management, claim review, and user referral services, among other things, to insurance companies, insurance brokers, and agency companies. Our insurance-related income amounted to
RMB738.6 million (US ) in the second quarter of 2025, representing an increase of$103.1 million 28.7% year-over-year fromRMB573.8 million for the second quarter of 2024, which was mainly due to the increase in technical service income. On a quarter-over-quarter basis, insurance-related income increased by12.2% . - Crowdfunding service fees represent the service income earned when patients successfully withdraw the proceeds from their crowdfunding campaigns. OurÌýrole is to operate the Waterdrop Medical Crowdfunding platform to provide crowdfunding related services through the internet, enabling patients with significant medical bills to seek help from caring hearts through technology (the "medical crowdfunding services"). OurÌýmedical crowdfunding services generally consist of providing technical and internet support, managing, reviewing and supervising the crowdfunding campaigns, providing comprehensive risk management and anti-fraud measures, and facilitating the collection and transfer of the funds. For the second quarter of 2025,Ìýwe generated
RMB67 .4Ìýmillion (US .4Ìýmillion) in service fees, representing a slight decrease of$9 2.7% year-over-year fromRMB69 .3Ìýmillion for the secondÌýquarter of 2024.ÌýOn a quarter-over-quarter basis, crowdfunding service fees remained stable. - Digital clinical trial solution income represents the service income earned from our customers mainly including biopharmaceutical companies and leading biotechnology companies. We match qualified and suitable patients for enrollment in clinical trials for our customers and generate digital clinical trial solution revenue for successful matches and we typically charge our customers a fixed unit price per successful match. For the second quarter of 2025, our digital clinical trial solution income amounted to
RMB27.7 million (US ), representing an increase of$3.9 million 34.2% fromRMB20.7 million in the same period of 2024. On a quarter-over-quarter basis, digital clinical trial solution income increased by20.6% .
Operating costs and expenses
Operating costs and expenses increased by
- Operating costs increased by
30.5% year over year toRMB416.5 million (US ) for the second quarter of 2025, as compared with$58.1 million RMB319.1 million for the second quarter of 2024, which was primarily driven by (i) an increase ofRMB73.4 million in costs of referral and service fees, (ii) an increase ofRMB10.8 million in the costs for the crowdfunding consultants team, and (iii) an increase ofRMB7.0 million in personnel costs.ÌýOn a quarter-over-quarter basis, operating costs increased by11.3% fromRMB374.2 million , primarily due toÌý(i) an increase ofRMB25.0 million in costs of referral and service fees, and (ii) an increase ofRMB7.3 million in personnel costs.Ìý - Sales and marketing expenses increased by
26.3% year-over-year toRMB198.8 million (US ) for the second quarter of 2025, as compared with$27.7 million RMB157.4 million for the same quarter of 2024. The increase was primarily due to an increase ofRMB44.3 million in marketing expenses for third-party traffic channels. On a quarter-over-quarter basis, sales and marketing expenses increased by15.3% fromRMB172.4 million , primarily due to an increase ofRMB25.4 million in marketing expenses for third-party traffic channels. - General and administrative expenses decreased by
21.9% year-over-year toRMB73.4 million (US ) for the second quarter of 2025, compared with$10.2 million RMB94.0 million for the same quarter of 2024. The year-over-year variance was due to (i) a decrease ofRMB13.4 million in allowance for credit losses, and (ii) a decrease ofRMB6.0 million in professional service fees. On a quarter-over-quarter basis, general and administrative expenses decreased by2.1% fromRMB74.9 million , due to our effective cost control measures. - Research and development expenses remained stable at
RMB51.9 million (US ) for the second quarter of 2025, maintaining nearly the same level as$7.3 million RMB53.3 million for the same period of 2024. On a quarter-over-quarter basis, research and development expenses decreased by7.6% fromRMB56.2 million . The decrease was primarily due to a decrease ofRMB3.8 million in personnel costs and share-based compensation expenses.
Operating profitÌýfor the secondÌýquarter of 2025 was
Interest incomeÌýfor the secondÌýquarter of 2025 was
Income tax benefitÌýfor the secondÌýquarter of 2025 was
Net profit attributable to the Company's ordinary shareholders for the secondÌýquarter of 2025 was
Adjusted net profit attributable to the Company's ordinary shareholders (non-GAAP(1)) for the second quarter of 2025 was
Cash position(2)
As of JuneÌý30, 2025, cash positionÌýof the Company was
(1) See the sections entitled "Non-GAAP Financial Measure" and "Reconciliations of GAAP and Non-GAAP Results" for more information about the non-GAAP |
(2) Cash position includes cash and cash equivalents, short-term investments, and long-term debt investments included in long-term investments. |
Share Repurchase Programs
Pursuant to the share repurchase programs launched in September 2021, September 2022, September 2023 and September 2024, respectively, we had cumulatively repurchased approximately 55.7 million ADSs from the open market with cash for a total consideration of approximately
Our Board has approved a new share repurchase program whereby the Company is authorized to repurchase its own ordinary shares in the form of American depository shares with an aggregate value of up toÌýUS
Cash Dividend
The Board has approved a cash dividend ofÌýUS
Supplemental Information
We organize and report our business inÌýthe followingÌýoperatingÌýsegments:
- Insurance, which mainly includes insurance brokerage service and technical service;
- Crowdfunding, which mainly includes crowdfundingÌýservice; and
- Others, which do not individually or in the aggregate meet the quantitative and qualitative thresholds to be individually reportable and are aggregated.
The table below sets forth the segment operating results, with three-month and six-month ended June 30, 2024 retrospectively adjusted to conform to this presentation.
For the Three Months EndedÌý | For the Six Months EndedÌý | |||||||||||||
June 30, 2024 | March 31, 2025 | June 30, 2025 | June 30, 2024 | June 30, 2025 | ||||||||||
RMB | RMB | RMB | USD | RMB | RMB | USD | ||||||||
(All amounts in thousands) | ||||||||||||||
Operating revenue, net | ||||||||||||||
Ìý±õ²Ô²õ³Ü°ù²¹²Ô³¦±ðÌý | 573,832 | 657,988 | 738,561 | 103,099 | 1,180,609 | 1,396,549 | 194,951 | |||||||
Ìý°ä°ù´Ç·É»å´Ú³Ü²Ô»å¾±²Ô²µÌý | 69,323 | 67,131 | 67,419 | 9,411 | 136,673 | 134,550 | 18,782 | |||||||
Ìý°¿³Ù³ó±ð°ù²õÌý | 33,001 | 28,575 | 31,979 | 4,465 | 63,574 | 60,554 | 8,453 | |||||||
Total consolidated operatingÌýrevenue, net | 676,156 | 753,694 | 837,959 | 116,975 | 1,380,856 | 1,591,653 | 222,186 | |||||||
Operating costs and expenses | ||||||||||||||
Ìý±õ²Ô²õ³Ü°ù²¹²Ô³¦±ðÌý | (450,877) | (506,575) | (567,642) | (79,239) | (928,491) | (1,074,217) | (149,955) | |||||||
Ìý°ä°ù´Ç·É»å´Ú³Ü²Ô»å¾±²Ô²µÌý | (92,259) | (97,299) | (99,519) | (13,892) | (191,846) | (196,818) | (27,475) | |||||||
Ìý°¿³Ù³ó±ð°ù²õÌý | (60,451) | (54,000) | (58,620) | (8,183) | (122,456) | (112,620) | (15,721) | |||||||
Operating profit/(loss) | ||||||||||||||
Ìý±õ²Ô²õ³Ü°ù²¹²Ô³¦±ðÌý | 122,955 | 151,413 | 170,919 | 23,860 | 252,118 | 322,332 | 44,996 | |||||||
Ìý°ä°ù´Ç·É»å´Ú³Ü²Ô»å¾±²Ô²µÌý | (22,936) | (30,168) | (32,100) | (4,481) | (55,173) | (62,268) | (8,693) | |||||||
Ìý°¿³Ù³ó±ð°ù²õÌý | (27,450) | (25,425) | (26,641) | (3,718) | (58,882) | (52,066) | (7,268) | |||||||
Total segment operating profit | 72,569 | 95,820 | 112,178 | 15,661 | 138,063 | 207,998 | 29,035 | |||||||
Unallocated items* | (20,205) | (19,927) | (14,842) | (2,072) | (39,335) | (34,769) | (4,854) | |||||||
Total consolidated operatingÌýprofit | 52,364 | 75,893 | 97,336 | 13,589 | 98,728 | 173,229 | 24,181 | |||||||
Total other income | 38,366 | 41,690 | 40,032 | 5,589 | 81,147 | 81,722 | 11,408 | |||||||
Consolidated profit beforeÌýincome tax | 90,730 | 117,583 | 137,368 | 19,178 | 179,875 | 254,951 | 35,589 | |||||||
* The share-based compensation represents unallocated items in the segment information because our management does |
Recent Development
In order to strengthen synergies between the Group and Shenlanbao, the Group entered into a new share purchase agreement with all non-controlling shareholders of Shenlanbao to acquire all remaining equity interests in Shenlanbao. All of the closing conditions included in the new agreement had been met as of June 30, 2025, and since then, Shenlanbao has been
With full ownership, the Group can drive stronger strategic synergy. This acquisition also enables us to strengthen our service differentiation and extend technology deployment. By leveraging the Group's industry insights while preserving Shenlanbao's operational independence, we will unlock new growth opportunities for the enlarged entity.
Exchange Rate
This announcement contains translations of certain RMB amounts into
Non-GAAP Financial Measure
The Company usesÌýnon-GAAP financial measure, adjusted net profit attributable to our ordinary shareholders, in evaluating the Company's operating results and for financial and operational decision-making purposes. Adjusted net profit attributable to our ordinary shareholders represents net profitÌýattributable to our ordinary shareholdersÌýexcluding share-based compensation expenseÌýattributable to our ordinary shareholders and foreign currency exchange gain or losses. Such adjustments have no impact on income tax.
The non-GAAP financial measure isÌýnot presented in accordance with
The Company mitigates these limitations by reconciling the non-GAAP financial measure to the most comparable
For more information on the non-GAAP financial measure, please see the table captioned "Reconciliation of GAAP and Non-GAAP Results" set forth at the end of this press release.
Safe Harbor Statement
This press release contains statements that may constitute "forward-looking" statements pursuant to the "safe harbor" provisions of the
Conference Call Information
Waterdrop's management team will hold a conference call on September 4, 2025 at 8:00 AM
International: | 1-412-317-6061 |
United States Toll Free: | 1-888-317-6003 |
Hong Kong Toll Free: | 800-963976 |
852-58081995 | |
Mainland | 4001-206115 |
Chinese Line (Mandarin)ÌýEntry Number: | 0088782 |
English Interpretation Line (Listen-onlyÌýMode) Entry Number: | 7013962 |
Participants can choose between the Chinese and the English interpretation lines. Please note that the English interpretation option will be in listen-only mode. Please dial in 15 minutes before the call is scheduled to begin and provide the Elite Entry Number to join the call.
Telephone replays will be accessible two hours after the conclusion of the conference call through September 11, 2025 by dialing the following numbers:
United States Toll Free: | 1-877-344-7529 |
International: | 1-412-317-0088 |
Chinese Line Access Code: | 4409082 |
English Interpretation Line Access Code: | 3334217 |
A live and archived webcast of the conference call will also be available at the Company's investor relations website at .
About Waterdrop Inc.
Waterdrop Inc. (NYSE: WDH) is a leading technology platform dedicated to insurance and healthcare service with a positive social impact. Founded in 2016, with the comprehensive coverage of Waterdrop Insurance Marketplace and Waterdrop Medical Crowdfunding, Waterdrop aims to bring insurance and healthcare service to billions through technology. For more information, please visit .
For investor inquiries, please contact
Waterdrop Inc.
[email protected]Ìý
WATERDROP INC. | |||||
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS | |||||
(All amounts in thousands, unless otherwise noted) | |||||
As ofÌý | |||||
December 31, 2024 | June 30, 2025 | ||||
RMB | RMB | USD | |||
Assets | |||||
Current assets | |||||
ÌýÌýÌýÌýÌýÌý Cash and cash equivalents | 986,323 | 722,006 | 100,788 | ||
ÌýÌýÌýÌýÌýÌý Restricted cashÌý | 520,588 | 637,817 | 89,036 | ||
ÌýÌýÌýÌýÌýÌý Short-term investments | 1,612,619 | 942,293 | 131,539 | ||
ÌýÌýÌýÌýÌýÌý Accounts receivable, netÌý | 716,206 | 838,571 | 117,060 | ||
ÌýÌýÌýÌýÌýÌý Current contract assetsÌý | 619,436 | 679,254 | 94,820 | ||
ÌýÌýÌýÌýÌýÌý Amount due from related parties | 257 | 315 | 44 | ||
ÌýÌýÌýÌýÌýÌý Prepaid expense and other assets | 182,641 | 202,457 | 28,263 | ||
Total current assets | 4,638,070 | 4,022,713 | 561,550 | ||
Non-current assets | |||||
ÌýÌýÌýÌýÌýÌý Non-current contract assets | 153,749 | 195,902 | 27,347 | ||
ÌýÌýÌýÌýÌýÌý Property, equipment and software, net | 240,024 | 246,610 | 34,425 | ||
ÌýÌýÌýÌýÌýÌý Intangible assets, net | 153,011 | 152,946 | 21,350 | ||
ÌýÌýÌýÌýÌýÌý Long-term investments | 1,114,160 | 1,786,589 | 249,398 | ||
ÌýÌýÌýÌýÌýÌý Right of use assets, net | 46,872 | 17,185 | 2,399 | ||
ÌýÌýÌýÌýÌýÌý Deferred tax assets | 27,028 | 20,332 | 2,838 | ||
ÌýÌýÌýÌýÌýÌý Goodwill | 80,751 | 80,751 | 11,272 | ||
Total non-current assets | 1,815,595 | 2,500,315 | 349,029 | ||
Total assets | 6,453,665 | 6,523,028 | 910,579 | ||
Liabilities, Mezzanine Equity and Shareholders' | |||||
Current liabilities | |||||
ÌýÌýÌýÌýÌýÌý Amount due to related parties | 10,616 | 9,834 | 1,373 | ||
ÌýÌýÌýÌýÌýÌý Insurance premium payablesÌý | 537,344 | 608,994 | 85,012 | ||
ÌýÌýÌýÌýÌýÌý Accrued expenses and other current liabilities | 704,035 | 724,189 | 101,093 | ||
ÌýÌýÌýÌýÌýÌý Short-term loans | 198,373 | 63,000 | 8,794 | ||
ÌýÌýÌýÌýÌýÌý Current lease liabilities | 34,573 | 11,866 | 1,656 | ||
Total current liabilitiesÌý | 1,484,941 | 1,417,883 | 197,928 | ||
Non-current liabilities | |||||
ÌýÌýÌýÌýÌýÌý Non-current lease liabilities | 10,971 | 4,948 | 691 | ||
ÌýÌýÌýÌýÌýÌý Deferred tax liabilities | 84,185 | 87,602 | 12,229 | ||
Total non-current liabilities | 95,156 | 92,550 | 12,920 | ||
Total liabilities | 1,580,097 | 1,510,433 | 210,848 | ||
Mezzanine Equity | |||||
ÌýÌýÌýÌýÌýÌý Redeemable non-controlling interests | 76,133 | - | - | ||
Shareholders' equity | |||||
ÌýÌýÌýÌýÌýÌý Class A ordinary shares | 112 | 114 | 16 | ||
ÌýÌýÌýÌýÌýÌý Class B ordinary shares | 27 | 27 | 4 | ||
ÌýÌýÌýÌýÌýÌý Treasury stock | (15) | (15) | (2) | ||
ÌýÌýÌýÌýÌýÌý Additional paid-in capital | 6,832,214 | 6,847,516 | 955,876 | ||
ÌýÌýÌýÌýÌýÌý Accumulated other comprehensive income | 159,550 | 111,052 | 15,502 | ||
ÌýÌýÌýÌýÌýÌý Accumulated deficit | (2,194,453) | (1,946,099) | (271,665) | ||
Total shareholders' equity | 4,797,435 | 5,012,595 | 699,731 | ||
Total liabilities, mezzanine equity and shareholders' equity | 6,453,665 | 6,523,028 | 910,579 |
Ìý
WATERDROP INC. | ||||||||||||||
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME | ||||||||||||||
(All amounts in thousands, except for share and per share data, or otherwise noted) | ||||||||||||||
For the Three Months EndedÌý | For the Six Months EndedÌý | |||||||||||||
June 30, 2024 | March 31, 2025 | June 30, 2025 | June 30, 2024 | June 30, 2025 | ||||||||||
RMB | RMB | RMB | USD | RMB | RMB | USD | ||||||||
Operating revenue, net | 676,156 | 753,694 | 837,959 | 116,975 | 1,380,856 | 1,591,653 | 222,186 | |||||||
Operating costs and expenses(i) | ||||||||||||||
ÌýOperating costsÌý | (319,101) | (374,218) | (416,493) | (58,140) | (650,344) | (790,711) | (110,379) | |||||||
ÌýSales and marketing expensesÌý | (157,413) | (172,396) | (198,785) | (27,749) | (339,559) | (371,181) | (51,815) | |||||||
ÌýGeneral and administrative expensesÌý | (93,978) | (74,943) | (73,400) | (10,246) | (182,939) | (148,343) | (20,708) | |||||||
ÌýResearch and development expensesÌý | (53,300) | (56,244) | (51,945) | (7,251) | (109,286) | (108,189) | (15,103) | |||||||
Total operating costs and expenses | (623,792) | (677,801) | (740,623) | (103,386) | (1,282,128) | (1,418,424) | (198,005) | |||||||
Operating profit | 52,364 | 75,893 | 97,336 | 13,589 | 98,728 | 173,229 | 24,181 | |||||||
Other income | ||||||||||||||
ÌýInterest incomeÌý | 37,510 | 33,814 | 29,534 | 4,123 | 77,314 | 63,348 | 8,843 | |||||||
ÌýForeign currency exchange (loss)/gainÌý | (444) | (2,103) | 2,656 | 371 | 1,070 | 553 | 77 | |||||||
ÌýOthers, netÌý | 1,300 | 9,979 | 7,842 | 1,095 | 2,763 | 17,821 | 2,488 | |||||||
Profit before income tax | 90,730 | 117,583 | 137,368 | 19,178 | 179,875 | 254,951 | 35,589 | |||||||
ÌýIncome tax (expense)/benefitÌý | (7,026) | (13,328) | 2,852 | 398 | (15,614) | (10,476) | (1,462) | |||||||
Net profitÌý | 83,704 | 104,255 | 140,220 | 19,576 | 164,261 | 244,475 | 34,127 | |||||||
ÌýNet (loss)/profit attributable to mezzanine equity classified as non- | (4,586) | (3,940) | 61 | 9 | (4,661) | (3,879) | (541) | |||||||
Net profit attributable to ordinary shareholders | 88,290 | 108,195 | 140,159 | 19,567 | 168,922 | 248,354 | 34,668 | |||||||
Other comprehensive income: | ||||||||||||||
ÌýForeign currency translation adjustment, net of taxÌý | 13,497 | (14,056) | (33,283) | (4,646) | 38,640 | (47,339) | (6,608) | |||||||
ÌýUnrealized gain/(loss) on available for sale investments, net of taxÌý | - | 17,612 | (18,771) | (2,620) | - | (1,159) | (162) | |||||||
Total comprehensive income | 97,201 | 107,811 | 88,166 | 12,310 | 202,901 | 195,977 | 27,357 | |||||||
ÌýTotal comprehensive (loss)/profit attributable to mezzanine equity | (4,586) | (3,940) | 61 | 9 | (4,661) | (3,879) | (541) | |||||||
Total comprehensive income attributable toÌýordinary shareholders | 101,787 | 111,751 | 88,105 | 12,301 | 207,562 | 199,856 | 27,898 | |||||||
Weighted average number of ordinary shares usedÌýin computing | ||||||||||||||
ÌýBasicÌý | 3,660,589,600 | 3,620,380,862 | 3,608,253,358 | 3,608,253,358 | 3,678,604,386 | 3,614,283,609 | 3,614,283,609 | |||||||
ÌýDilutedÌý | 3,734,346,444 | 3,711,999,000 | 3,711,084,352 | 3,711,084,352 | 3,745,404,276 | 3,711,508,175 | 3,711,508,175 | |||||||
Net profit per share attributable to ordinary shareholders | ||||||||||||||
ÌýBasicÌý | 0.02 | 0.03 | 0.04 | 0.01 | 0.05 | 0.07 | 0.01 | |||||||
ÌýDilutedÌý | 0.02 | 0.03 | 0.04 | 0.01 | 0.05 | 0.07 | 0.01 | |||||||
(i)ÌýÌýShare-based compensation expenses are included in the operating costs and expenses as follows.Ìý | ||||||||||||||
For the Three Months EndedÌý | For the Six Months EndedÌý | |||||||||||||
June 30, 2024 | March 31, 2025 | June 30, 2025 | June 30, 2024 | June 30, 2025 | ||||||||||
RMB | RMB | RMB | USD | RMB | RMB | USD | ||||||||
Sales and marketing expenses | (1,320) | (1,899) | (1,949) | (272) | (3,140) | (3,848) | (537) | |||||||
General and administrative expenses | (16,285) | (15,527) | (11,899) | (1,661) | (30,612) | (27,426) | (3,829) | |||||||
Research and development expenses | (2,600) | (2,501) | (994) | (139) | (5,583) | (3,495) | (488) | |||||||
TotalÌý | (20,205) | (19,927) | (14,842) | (2,072) | (39,335) | (34,769) | (4,854) |
Ìý
WATERDROP INC. | ||||||||||||||
RECONCILIATIONS OF GAAP AND NON-GAAP RESULTS | ||||||||||||||
(All amounts in thousands, unless otherwise noted) | ||||||||||||||
For the Three Months EndedÌý | For the Six Months EndedÌý | |||||||||||||
June 30, 2024 | March 31, 2025 | June 30, 2025 | June 30, 2024 | June 30, 2025 | ||||||||||
RMB | RMB | RMB | USD | RMB | RMB | USD | ||||||||
Net profit attributable to the Company'sÌýordinary | 88,290 | 108,195 | 140,159 | 19,567 | 168,922 | 248,354 | 34,668 | |||||||
Add: | ||||||||||||||
ÌýShare-based compensation expense attributableÌýto the | 20,015 | 19,750 | 14,144 | 1,974 | 39,274 | 33,894 | 4,731 | |||||||
ÌýForeign currency exchange loss/(gain)Ìý | 444 | 2,103 | (2,656) | (371) | (1,070) | (553) | (77) | |||||||
Adjusted net profit attributable to theÌýCompany's ordinary | 108,749 | 130,048 | 151,647 | 21,170 | 207,126 | 281,695 | 39,322 |
Ìý
View original content:
SOURCE Waterdrop Inc.